Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Income from Continuing Operations (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Income from Continuing Operations for 13 consecutive years, with 71870000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 8.53% to 71870000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 390949000.0, a 5.04% decrease, with the full-year FY2025 number at 390949000.0, down 5.04% from a year prior.
  • Income from Continuing Operations was 71870000.0 for Q4 2025 at Iovance Biotherapeutics, up from 91258000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 71870000.0 in Q4 2025 to a low of 116359000.0 in Q4 2023.
  • A 3-year average of 100595250.0 and a median of 106949000.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: soared 32.47% in 2024, then fell 15.0% in 2025.
  • Iovance Biotherapeutics' Income from Continuing Operations stood at 116359000.0 in 2023, then surged by 32.47% to 78573000.0 in 2024, then grew by 8.53% to 71870000.0 in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Income from Continuing Operations are 71870000.0 (Q4 2025), 91258000.0 (Q3 2025), and 111620000.0 (Q2 2025).